Moberg Pharma receives approval from the EMA's Paediatric Committee
Moberg Pharma AB has received approval for its pediatric plan for MOB-015 from the EMA's pediatric committee (PDCO), paving the way for a full marketing authorization application. This approval allows Moberg to conduct a pediatric study involving 30 children aged 6-17, expected to commence in the latter half of 2022. The company anticipates submitting the registration application for MOB-015 in Europe this year, with market approval expected in 2023. This decision enhances data exclusivity in Europe for up to ten years, bolstering Moberg's intellectual property protection.
- Approval for the pediatric plan for MOB-015 enables a full marketing authorization application.
- Conducting a pediatric study with 30 children supports the clinical program.
- Potential ten years of data exclusivity in Europe strengthens intellectual property.
- None.
STOCKHOLM, Sept. 22, 2021 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) today announces that it has received approval of the pediatric plan for MOB-015 from EMA's paediatric committee (PDCO). This approval enables the company to pursue a full marketing authorization application providing up to ten years of exclusivity in Europe following approval. The company's timeline remains, with planned submission for MOB-015 in Europe this year and expected market approval in 2023.
Today's positive decision means that Moberg Pharma will conduct a pediatric study during and after the approval process for MOB-015. The study includes 30 children, 6 to 17 years of age, and will be initiated in the second half of 2022. The pediatric study supplements the already completed clinical program, including the two phase 3 studies with a total of more than 800 patients, where the primary endpoint was achieved in both the North American and European studies.
"The approval enables data exclusivity in Europe for up to 10 years and further strengthens our intellectual property protection of MOB-015. It is an important milestone towards our goal to submit a registration application for MOB-015 in Europe this year," says Anna Ljung, CEO of Moberg Pharma AB.
For additional information, please contact:
Anna Ljung, CEO, Moberg Pharma
Telephone: +46 707 66 60 30
E-mail: anna.ljung@mobergpharma.se
This information, Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 a.m. CET on September 22, 2021.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Moberg Pharma receives approval from the EMA’s Paediatric Committee |
View original content:https://www.prnewswire.com/news-releases/moberg-pharma-receives-approval-from-the-emas-paediatric-committee-301382355.html
SOURCE Moberg Pharma
FAQ
What recent approval did Moberg Pharma receive for MOB-015?
When is Moberg Pharma planning to submit the registration application for MOB-015?
What is the timeline for the pediatric study related to MOB-015?
How long will Moberg Pharma have data exclusivity in Europe after approval?
What are the expected outcomes of the pediatric study for MOB-015?
